{"id":"centanafadine-sr","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of all three monoamine neurotransmitters (serotonin, norepinephrine, and dopamine), centanafadine increases their synaptic concentrations. The sustained-release (SR) formulation provides prolonged therapeutic levels. This triple mechanism distinguishes it from selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).","oneSentence":"Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:20.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT07465731","phase":"PHASE1","title":"A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-10-27","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT07253441","phase":"PHASE1","title":"A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2024-08-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":174},{"nctId":"NCT05113953","phase":"PHASE2","title":"A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2021-12-22","conditions":"Binge-Eating Disorder","enrollment":147},{"nctId":"NCT05066724","phase":"PHASE2","title":"Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2021-09-15","conditions":"Smoking Cessation","enrollment":50},{"nctId":"NCT03605849","phase":"PHASE3","title":"A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-02-14","conditions":"Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder","enrollment":662},{"nctId":"NCT03605680","phase":"PHASE3","title":"A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-01-16","conditions":"Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder","enrollment":604},{"nctId":"NCT02827513","phase":"PHASE1","title":"A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-12","conditions":"Adult Attention-deficit Hyperactivity Disorder (ADHD)","enrollment":16},{"nctId":"NCT02547428","phase":"PHASE2","title":"Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-08-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":85},{"nctId":"NCT03605836","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-01-16","conditions":"Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder","enrollment":590},{"nctId":"NCT01939353","phase":"PHASE2","title":"Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-10-03","conditions":"Adult ADHD","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EB-1020","centanafadine","centanafadine XR"],"phase":"phase_3","status":"active","brandName":"Centanafadine SR","genericName":"Centanafadine SR","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine. Used for Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}